Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study-Reference-Cited by-同舟云学术

Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study

Published:2023-03 Issue: Volume:182 Page:66-76
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Velev Maud^ORCID,Dalban Cécile,Chevreau Christine,Gravis Gwenaelle,Negrier Sylvie,Laguerre Brigitte,Gross-Goupil Marine,Ladoire Sylvain,Borchiellini Delphine,Geoffrois Lionnel,Joly Florence,Priou Frank,Barthelemy Philippe,Laramas Mathieu,Narciso Berangère,Thiery-Vuillemin Antoine,Berdah Jean-François,Ferrari Victoria,Dominique Thomas Quentin^ORCID,Mione Cécile,Curcio Hubert^ORCID,Oudard Stephane,Tantot Florence,Escudier Bernard,Chabaud Sylvie^ORCID,Albiges Laurence,Thibault Constance^ORCID

Funder

Unicancer

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Cancer statistics, 2021;Siegel;CA Cancer J Clin,2021

2. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis;Bianchi;Ann Oncol,2012

3. Clear cell renal cell carcinoma bone metastasis: what should be considered in prognostic evaluation;Huang;Eur J Surg Oncol,2019

4. Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor;Grassi;Future Oncol,2014

5. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Implications of bone metastasis on response to systemic therapy in patients with advanced renal cell carcinoma: A systematic literature review;Cancer Treatment Reviews;2024-09

2. Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study;Cancer Immunology, Immunotherapy;2024-07-02

3. Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation;Journal for ImmunoTherapy of Cancer;2024-05

4. Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of Meet-URO15 study;2024-02-28

5. Immunotherapy targeting PD‑1/PD‑L1: A potential approach for the treatment of cancer bone metastases (Review);International Journal of Oncology;2024-02-13